Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Jagannath S, et al. Among authors: orlowski rz. Cancer. 2005 Mar 15;103(6):1195-200. doi: 10.1002/cncr.20888. Cancer. 2005. PMID: 15690325 Free article.
Proteasome inhibitors in cancer therapy.
Orlowski RZ. Orlowski RZ. Methods Mol Biol. 2005;301:339-50. doi: 10.1385/1-59259-895-1:339. Methods Mol Biol. 2005. PMID: 15917644 Review.
Proteasome inhibitors in the treatment of multiple myeloma.
Shah JJ, Orlowski RZ. Shah JJ, et al. Among authors: orlowski rz. Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10. Leukemia. 2009. PMID: 19741722 Free PMC article. Review.
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Hunsucker SA, et al. Among authors: orlowski rz. Br J Haematol. 2011 Mar;152(5):579-92. doi: 10.1111/j.1365-2141.2010.08533.x. Epub 2011 Jan 17. Br J Haematol. 2011. PMID: 21241278 Free PMC article.
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Shah J, et al. Among authors: orlowski rz. Cancer. 2011 Aug 15;117(16):3758-62. doi: 10.1002/cncr.25937. Epub 2011 Feb 15. Cancer. 2011. PMID: 21328327 Free PMC article. Clinical Trial.
368 results